Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496234 · ClinicalTrials.gov registry record
The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery
A clinical trial, sponsored by Sapere Bio.
- Completed
- Registry status
- 186
- Enrollment target
NCT02496234 is a clinical trial that has completed, run by Sapere Bio. The registered enrollment target is 186 participants.
The verdict
NCT02496234 has completed, sponsored by Sapere Bio.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at higher risk for AKI and current risk predictor scores that are based on clinical and demographic information are inadequate. Therefore, a diagnostic test for predicting AKI risk in this clinical context would assist clinicians to optimize surgical strategy and postoperative care to prevent CSA-AKI occurrence and improve patient outcomes. The primary purpose of this study is to measure the association between baseline expression of senescence markers in blood using SenesceTest and the occurrence of CSA-AKI post surgery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496234
The ClinicalTrials.gov registry entry for NCT02496234 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sapere Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02496234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02496234 about?
NCT02496234 is a clinical study titled "The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery". Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at...
What is the current status of trial NCT02496234?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2015-07. Estimated completion is 2016-07.
Who is sponsoring clinical trial NCT02496234?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.